CJC-1295 research guide for Yanase. Covers DAC vs no-DAC forms, half-life differences, purity testing, and how to source quality CJC-1295 for research.
Most researchers searching for CJC-1295 in Yanase rapidly learn that local retail options are essentially nonexistent. What this means for Yanase researchers is that your location matters far less than your ability to assess COA data — and those evaluation tools are accessible to anyone. Separating properly characterised CJC-1295 from the rest of the market comes down to three things: an HPLC chromatogram documenting ≥98% purity, mass spec data confirming the correct molecular weight, and a batch-specific endotoxin panel. This guide gives Yanase researchers the framework to assess vendor quality rigorously and source research-grade CJC-1295 with confidence.
The Science Behind CJC-1295
CJC-1295 with DAC (Drug Affinity Complex) is a GHRH analogue with an extended half-life achieved through DAC technology that enables covalent binding to albumin. This modification extends the half-life from minutes (for native GHRH) to approximately 6-8 days, creating a sustained elevation in basal GH levels rather than the pulsatile pattern produced by GHRP compounds. This pharmacokinetic distinction is significant for research design: CJC-1295 based on CJC-1295 with DAC produces a different GH secretion pattern than GHRP compounds, with different downstream effects on IGF-1 and protein synthesis. Researchers in Yanase comparing compounds in this class should account for these pharmacokinetic differences in their experimental design.
How to Source CJC-1295 — Vendor Guide
The first step for any Yanase researcher sourcing CJC-1295 is finding vendors with verified community track records — search results alone are too heavily influenced by marketing spend. Endotoxin testing in the COA is essential for any injectable research use — endotoxins from microbial contamination can trigger dangerous inflammatory cascades even at very low concentrations. Positive vendor signals beyond COA quality: established track record of at least two years, customer service that can discuss analytical methods, and cold chain packaging that protects product integrity. Keep lyophilised CJC-1295 at freezer temperature (−20°C) until ready to use; reconstitute only the volume needed for upcoming use and return unused portion to the freezer.
Order CJC-1295 — ships to Yanase
COA-verified · International tracking · Research grade
CJC-1295 operates beyond the scope of approved drug regulation — researchers should understand that the known safety profile is based on academic studies rather than pharmaceutical approval data. Temperature excursions — even temporary temperature deviation — can cause partial degradation without any obvious sign; always verify cold chain was maintained during shipping. The most significant preventable safety hazard in CJC-1295 research is endotoxin from inadequately tested product — a documented endotoxin result in your specific batch certificate is the specific protection against this risk. PubMed represent the most comprehensive research databases for CJC-1295 research; favour indexed journal publications over preprints over conference abstracts or single case observations.
Frequently Asked Questions
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
